Lexicon Pharmaceuticals LXRX Business Segments — Royalties and other revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyIncomeNonoperating.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — royalties and other revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — royalties and other revenue?
- Lexicon Pharmaceuticals (LXRX) reported business segments — royalties and other revenue of $12K in Q1 2026.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — royalties and other revenue?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — royalties and other revenue has grown at a 3.9% compound annual growth rate (CAGR), from $139K to $156K.
- What does business segments — royalties and other revenue mean?
- Represents income generated from licensing intellectual property, patent rights, or other non-core operational activities within a specific business segment. This metric tracks passive revenue streams that do not stem directly from the primary sale of manufactured goods or services. It is a key indicator of the value derived from the company's proprietary technology portfolio.